Trial Profile
Open-label, randomised multicentre study of CAMPATH-1H versus basiliximab induction treatment and sirolimus versus tacrolimus maintenance treatment for the preservation of renal function in patients receiving kidney transplants.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Sirolimus (Primary) ; Antithymocyte globulin; Basiliximab; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms 3C
- 03 Jun 2020 Results (n=275) assessing effect of induction immunosuppression (ATG vs. Campath vs. Simulect) on the outcome of DCD kidneys, presented at the 2020 American Transplant Congress
- 23 Mar 2020 Status changed from active, no longer recruiting to completed.
- 26 Sep 2019 Planned End Date changed from 1 Feb 2019 to 1 Oct 2019.